Nexus Pharmaceuticals
Nexus Pharmaceuticals is a U.S.-based pharmaceutical manufacturer founded in 2003. It develops and commercializes specialty and generic injectable medicines, with a focus on difficult-to-formulate products and drug presentations for institutional and patient use.
Industries
N/A
Nexus Pharmaceuticals
Products
Ready-to-dilute multiple-dose injectable supplied in 2.5 mL and 5 mL vial fills.
Tacrolimus injectable supplied as a 5 mg/mL single-dose vial for use in immunosuppressive therapy, including prevention of organ rejection in liver and kidney transplant patients.
A refill kit for baclofen injection supplied in a vial-based presentation for use in care of patients with long-term severe spasticity.
Fluorescein injectable supplied in a 2 mL vial for diagnostic use in eye care.
Fluorescein injectable listed in a 5 mL vial presentation.
Injectable antifibrinolytic medication supplied in cartons of 10 bags and described for surgical bleeding control.
Ready-to-dilute multiple-dose injectable supplied in 2.5 mL and 5 mL vial fills.
Tacrolimus injectable supplied as a 5 mg/mL single-dose vial for use in immunosuppressive therapy, including prevention of organ rejection in liver and kidney transplant patients.
A refill kit for baclofen injection supplied in a vial-based presentation for use in care of patients with long-term severe spasticity.
Fluorescein injectable supplied in a 2 mL vial for diagnostic use in eye care.
Fluorescein injectable listed in a 5 mL vial presentation.
Injectable antifibrinolytic medication supplied in cartons of 10 bags and described for surgical bleeding control.
Expertise Areas
- Specialty and generic pharmaceuticals
- Injectable medicines
- Difficult-to-formulate drug products
- Hospital-use medications
Key Technologies
- Injectable drug formulation
- Vial-based dosage forms
- Ready-to-dilute injectable formulations
- Lyophilized drug presentation
Key People
Chief Executive Officer
Chief Operating Officer
Chief Scientific Officer
Vice President of Sales
Chief Executive Officer
Chief Operating Officer
Chief Scientific Officer
Vice President of Sales
News & Updates
The company announced FDA approval of a 5 mg/mL tacrolimus injection on February 14, 2025.
The company announced FDA approval of methylene blue injection for acquired methemoglobinemia on November 26, 2024.
The company announced FDA approval of a 5 mg/mL tacrolimus injection on February 14, 2025.
The company announced FDA approval of methylene blue injection for acquired methemoglobinemia on November 26, 2024.